Related Experiment Video
Updated: May 27, 2026
07:38
A General Method for Detecting Nitrosamide Formation in the In Vitro Metabolism of Nitrosamines by Cytochrome P450s
Published on: September 25, 2017
A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds
Man Chin Chung1, Priscila Longhin Bosquesi, Jean Leandro dos Santos
1Lapdesf- Laboratory of Drug Desing, Dept of Drugs and Medicines, School of Pharmaceutical Sciences, University of São Paulo State, Rodovia Araraquara- Jaú km1, cep 14802-901, Araraquara, SP, Brazil. chungmc@fcfar.unesp.br
Current Pharmaceutical Design
|November 15, 2011
Summary
Nitro compounds are vital in therapeutics but pose toxicity risks. This study explores how prodrugs enhance biological activity and reduce genotoxicity of nitro compounds through improved physicochemical properties.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Toxicology
Background:
- Nitro compounds are crucial in therapeutics, offering diverse pharmacological activities.
- Incorporating a nitro group alters molecular properties, potentially increasing mutagenicity and carcinogenicity.
- Nitro group reduction is linked to both antimicrobial/anti-protozoal activity and mutagenic effects.
Purpose of the Study:
- To review the toxicity associated with nitro compounds.
- To investigate the use of prodrugs to enhance biological activity and mitigate genotoxicity.
- To demonstrate that prodrugs can improve physicochemical properties without altering nitro reduction behavior.
Main Methods:
- Literature review on nitro compound toxicity and prodrug strategies.
- Analysis of physicochemical property modifications in prodrugs.
- Case examples of metronidazole and nitrofurazone prodrugs.
Main Results:
- Prodrugs can improve the therapeutic index of nitro compounds.
- Physicochemical enhancements in prodrugs lead to reduced genotoxicity.
- Biological activity is maintained or enhanced via prodrug strategies.
Conclusions:
- Prodrug design offers a viable approach to manage nitro compound toxicity.
- Prodrugs can optimize the balance between efficacy and safety for nitro-containing therapeutics.
- Targeted physicochemical improvements are key to successful nitro prodrug development.
More Related Videos
Related Concept Videos
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:202° Amines to N-Nitrosamines: Reaction with NaNO2
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
01:29Preparation of Amines: Reduction of Oximes and Nitro Compounds
Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
01:27Phase I Reactions: Reductive Reactions
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...